Ropes Wealth Advisors LLC Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

Ropes Wealth Advisors LLC decreased its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,454 shares of the company’s stock after selling 4,619 shares during the period. Ropes Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $3,100,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of MRK. Financial Avengers Inc. increased its stake in Merck & Co., Inc. by 115.8% in the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after buying an additional 176 shares during the last quarter. Moisand Fitzgerald Tamayo LLC increased its stake in Merck & Co., Inc. by 78.0% in the 4th quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after buying an additional 156 shares during the last quarter. Retirement Group LLC increased its stake in Merck & Co., Inc. by 116.4% in the 3rd quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after buying an additional 327 shares during the last quarter. Bellwether Advisors LLC increased its stake in shares of Merck & Co., Inc. by 460.0% during the 3rd quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock worth $31,000 after purchasing an additional 345 shares during the last quarter. Finally, Steward Financial Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 72.88% of the company’s stock.

NYSE:MRK traded down $0.42 during trading hours on Friday, hitting $90.41. The stock had a trading volume of 10,308,067 shares, compared to its average volume of 11,242,952. The company has a 50 day simple moving average of $83.97 and a two-hundred day simple moving average of $80.70. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.27 and a quick ratio of 1.02. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $91.40. The firm has a market capitalization of $228.63 billion, a price-to-earnings ratio of 16.17, a P/E/G ratio of 1.20 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The company had revenue of $15.90 billion during the quarter, compared to the consensus estimate of $14.64 billion. During the same period in the previous year, the firm posted $1.40 EPS. The firm’s revenue was up 31.6% compared to the same quarter last year. Equities research analysts anticipate that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Several equities research analysts have recently issued reports on the stock. SVB Leerink decreased their price target on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. StockNews.com assumed coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating for the company. Barclays raised their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. JPMorgan Chase & Co. decreased their price target on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research note on Friday, January 28th. Finally, Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $90.69.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.